• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.

作者信息

De Pas Tommaso M, Giovannini Monica, Manzotti Michela, Trifirò Giuseppe, Toffalorio Francesca, Catania Chiara, Spaggiari Lorenzo, Labianca Roberto, Barberis Massimo

机构信息

Medical Oncology Unit of Respiratory Tract and Sarcomas, New Drugs Development Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.

出版信息

J Clin Oncol. 2011 Dec 1;29(34):e819-22. doi: 10.1200/JCO.2011.36.2251. Epub 2011 Oct 31.

DOI:10.1200/JCO.2011.36.2251
PMID:22042963
Abstract
摘要

相似文献

1
Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.携带表皮生长因子受体（EGFR）突变且对吉非替尼敏感的肺大细胞神经内分泌癌
J Clin Oncol. 2011 Dec 1;29(34):e819-22. doi: 10.1200/JCO.2011.36.2251. Epub 2011 Oct 31.
2
Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.伴有表皮生长因子受体突变的大细胞神经内分泌癌：肺腺癌可能的转化形式
Respirology. 2012 Nov;17(8):1275-7. doi: 10.1111/j.1440-1843.2012.02258.x.
3
Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.具有表皮生长因子受体（EGFR）第19外显子插入的肺癌对吉非替尼治疗敏感。
J Thorac Oncol. 2014 Apr;9(4):e31-3. doi: 10.1097/JTO.0000000000000106.
4
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.一线使用吉非替尼治疗携带体细胞EGFR突变的晚期非小细胞肺癌患者。
J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5.
5
Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report.携带EGFR突变的肺腺癌组织学转化为大细胞神经内分泌癌：一例尸检病例报告
Intern Med. 2017;56(15):2013-2017. doi: 10.2169/internalmedicine.56.7452. Epub 2017 Aug 1.
6
Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung.阿柔比星单药治疗既往治疗的晚期肺大细胞神经内分泌癌患者。
Jpn J Clin Oncol. 2011 Jul;41(7):897-901. doi: 10.1093/jjco/hyr065. Epub 2011 Jun 2.
7
Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.伴有间变性淋巴瘤激酶（ALK）重排且对阿来替尼有反应的大细胞神经内分泌癌
Intern Med. 2018 Mar 1;57(5):713-716. doi: 10.2169/internalmedicine.9368-17. Epub 2017 Nov 20.
8
EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.在非小细胞肺癌中赋予对吉非替尼原发性耐药的表皮生长因子受体（EGFR）突变
N Engl J Med. 2005 Jul 14;353(2):207-8. doi: 10.1056/NEJM200507143530217.
9
Direct comparison of 3 PCR methods in detecting EGFR mutations in patients with advanced non-small-cell lung cancer.三种 PCR 方法检测晚期非小细胞肺癌患者表皮生长因子受体突变的直接比较。
Clin Lung Cancer. 2012 Sep;13(5):369-74. doi: 10.1016/j.cllc.2012.01.008. Epub 2012 Mar 10.
10
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.中国非小细胞肺癌患者表皮生长因子受体酪氨酸激酶结构域的吉非替尼敏感突变
Clin Cancer Res. 2005 Jun 15;11(12):4289-94. doi: 10.1158/1078-0432.CCR-04-2506.

引用本文的文献

1
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.肺大细胞神经内分泌癌的综合分子与临床特征
Nat Commun. 2025 Aug 19;16(1):7717. doi: 10.1038/s41467-025-63091-0.
2
Clinical needs and pathology's answers in neuroendocrine neoplasms of the lung.肺部神经内分泌肿瘤的临床需求与病理学解答
Pathologica. 2025 Jun;117(3):220-242. doi: 10.32074/1591-951X-N1102. Epub 2025 Jun 27.
3
Dual inhibition of GTP-bound KRAS and mTOR in lung adenocarcinoma and squamous cell carcinoma harboring KRAS G12C.
对携带KRAS G12C的肺腺癌和肺鳞癌中GTP结合型KRAS和mTOR的双重抑制
Cell Commun Signal. 2025 May 11;23(1):220. doi: 10.1186/s12964-025-02187-y.
4
Unravelling the complexity of -mutated lung adenocarcinoma: a unique case report with histological transformations and co-alteration acquisition.解析 - 突变型肺腺癌的复杂性：一例具有组织学转变和共改变获得的独特病例报告
Transl Lung Cancer Res. 2025 Feb 28;14(2):639-648. doi: 10.21037/tlcr-24-707. Epub 2025 Feb 27.
5
[Research Progress on Molecular Subtypes and Precision Therapy 
of Pulmonary Large Cell Neuroendocrine Carcinoma].[肺大细胞神经内分泌癌的分子亚型与精准治疗研究进展]
Zhongguo Fei Ai Za Zhi. 2025 Feb 20;28(2):146-154. doi: 10.3779/j.issn.1009-3419.2025.102.06.
6
Efficacy of cadonilimab and anlotinib combination in treating multiple drug‑resistant pulmonary large cell neuroendocrine carcinoma: A case report and literature review.卡度尼利单抗联合安罗替尼治疗多药耐药性肺大细胞神经内分泌癌的疗效：1例病例报告及文献复习
Oncol Lett. 2024 Oct 24;29(1):27. doi: 10.3892/ol.2024.14773. eCollection 2025 Jan.
7
Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma.大细胞神经内分泌癌的一种亚型——联合大细胞神经内分泌癌的临床特征及治疗管理
Front Oncol. 2024 Oct 22;14:1449490. doi: 10.3389/fonc.2024.1449490. eCollection 2024.
8
Perioperative serplulimab‑based chemoimmunotherapy in stage IV large cell neuroendocrine carcinoma of the lung: A case report.围手术期基于斯鲁利单抗的化疗免疫疗法治疗IV期肺大细胞神经内分泌癌：一例报告
Oncol Lett. 2024 Sep 12;28(5):547. doi: 10.3892/ol.2024.14680. eCollection 2024 Nov.
9
Advances in genetic profile and therapeutic strategy of pulmonary large cell neuroendocrine carcinoma.肺大细胞神经内分泌癌的基因特征及治疗策略进展
Front Med (Lausanne). 2024 Feb 27;11:1326426. doi: 10.3389/fmed.2024.1326426. eCollection 2024.
10
Clinical characteristics, treatment, and outcome of patients with large cell neuroendocrine carcinoma of the lung and brain metastases - data from a tertiary care center.肺和脑转移的大细胞神经内分泌癌患者的临床特征、治疗和转归——来自一家三级护理中心的数据。
Clin Exp Metastasis. 2024 Feb;41(1):25-32. doi: 10.1007/s10585-023-10250-6. Epub 2023 Dec 8.